Functional rescue experiments showed that reintroduction of miR-126 counteracts the tumor-suppressive effects of YTHDF2 depletion, indicating that the YTHDF2/miR-126 axis represents a critical oncogenic pathway and a potential therapeutic vulnerability in AML (50). The gene discussed is YTHDF2; the disease is acute myeloid leukemia.